InfraReDx Launches LipiScan To Evaluate Coronary Plaque
This article was originally published in The Gray Sheet
Executive Summary
InfraReDx is launching its catheter-based LipiScan coronary imaging system, which relies upon near-infrared spectroscopy to identify plaque most likely to cause heart attacks and death, following April 25 FDA 510(k) clearance of the device
You may also be interested in...
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
InfraReDx is in the final planning stages for its first randomized trial to secure a place for its LipiScan intracoronary imaging device in clinical practice
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
InfraReDx is in the final planning stages for its first randomized trial to secure a place for its LipiScan intracoronary imaging device in clinical practice
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
A randomized trial will measure the catheter-based system's ability to pick patients vulnerable to MI during stenting, but regardless of the data collection or the available technology, a major barrier standing in the way of LipiScan adoption is reimbursement.